

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of the Claims:

1-87. (canceled)

88.(new) A pharmaceutical composition comprising an inclusion complex of a modafinil compound and a cyclodextrin wherein the modafinil compound has an aqueous solubility of at least 10 mg/ml and the composition provides at least a 10% increase in the blood serum level of a modafinil compound in a mammal upon oral administration relative to the same amount of a modafinil compound in a solid oral dosage form.

89.(new) The composition of claim 88 wherein the composition provides at least a 25% increase in the blood serum level of a modafinil compound in a mammal upon oral administration relative to the same amount of a modafinil compound in a solid oral dosage form.

90.(new) The composition of claim 88 wherein the composition provides at least a 50% increase in the blood serum level of a modafinil compound in a mammal upon oral administration relative to the same amount of a modafinil compound in a solid oral dosage form.

91.(new) The composition of claims 88, 89, or 90 wherein the increase in the blood serum level is within the first hour of oral administration to the mammal.

92.(new) The composition of claims 88, 89, or 90 which has substantially the blood serum profile of FIG. 1.

93.(new) The composition of claims 88, 89, or 90 wherein the solid oral dosage form is a tablet.

94.(new) The composition of claims 88, 89, or 90 wherein the modafinil compound is modafinil.

95.(new) The composition of claims 88, 89, or 90 wherein the modafinil compound is the levorotatory form of modafinil.

96.(new) The composition of claims 88, 89, or 90 wherein the composition comprises 100 mg of the modafinil compound.

97.(new) The composition of claims 88, 89, or 90 wherein the composition comprises 200 mg of the modafinil compound.

98.(new) The composition of claims 88, 89, or 90 wherein the composition comprises 400 mg of the modafinil compound.